YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells
© Mantwill et al.; licensee BioMed Central Ltd. 2013
Received: 15 July 2013
Accepted: 13 September 2013
Published: 18 September 2013
The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence. In brain CSC, the PI3-K/AKT and the RAS/mitogen activated protein kinase (MAPK) pathways are found to be activated. In consequence, the human transcription factor YB-1, knowing to be responsible for the emergence of drug resistance and driving adenoviral replication, is phosphorylated and activated. With this knowledge, YB-1 was established in the past as a biomarker for disease progression and prognosis. This study determines the expression of YB-1 in glioblastoma (GBM) specimen in vivo and in brain CSC lines. In addition, the capacity of Ad-Delo3-RGD, an YB-1 dependent oncolytic adenovirus, to eradicate CSC was evaluated both in vitro and in vivo.
YB-1 expression was investigated by immunoblot and immuno-histochemistry. In vitro, viral replication as well as the capacity of Ad-Delo3-RGD to replicate in and, in consequence, to kill CSC was determined by real-time PCR and clonogenic dilution assays. In vivo, Ad-Delo3-RGD-mediated tumor growth inhibition was evaluated in an orthotopic mouse GBM model. Safety and specificity of Ad-Delo3-RGD were investigated in immortalized human astrocytes and by siRNA-mediated downregulation of YB-1.
YB-1 is highly expressed in brain CSC lines and in GBM specimen. Efficient viral replication in and virus-mediated lysis of CSC was observed in vitro. Experiments addressing safety aspects of Ad-Delo3-RGD showed that (i) virus production in human astrocytes was significantly reduced compared to wild type adenovirus (Ad-WT) and (ii) knockdown of YB-1 significantly reduced virus replication. Mice harboring othotopic GBM developed from a temozolomide (TMZ)-resistant GBM derived CSC line which was intratumorally injected with Ad-Delo3-RGD survived significantly longer than mice receiving PBS-injections or TMZ treatment.
The results of this study supported YB-1 based virotherapy as an attractive therapeutic strategy for GBM treatment which will be exploited further in multimodal treatment concepts.
KeywordsCancer stem cells YB-1 Virotherapy Oncolytic virus Temozolomide
GBM is among the most deadly human cancers. Despite modern diagnosis and improved treatment regimens, including surgical resection followed by radiation and chemotherapy with TMZ, the prognosis for patients with GBM remains poor with a median survival after diagnosis of less than 15 months [1, 2]. Thus, new GBM therapeutic strategies are desperately needed. Considerable research efforts have been focused on dissecting the role of cancer stem cells (CSC) also referred to as tumor initiating cells (TIC), in cancer progression and recurrence [3, 4]. CSC have been described in several tumor types, including GBM [5, 6]. A number of studies have explored their role in overall tumor treatment resistance producing contradictory results [7–9]. Still, the detailed mechanisms of treatment resistance have to be characterized. Nevertheless, it is currently believed that CSCs are responsible for tumor initiation, progression and relapse, and that depletion of these cells is obligatory to cure patients.
On the transcriptional and protein level several signaling pathways, including PI3-K/AKT and the RAS/MAPK pathway, have been identified in brain CSC [10–12]. One of the downstream phosphorylation substrates of both pathways is YB-1, a multifunctional protein regulating transcription and translation . However, apart from these important results very little is known about the expression of YB-1 in CSC. The mouse homologue YB-1 is widely expressed throughout early mouse development, including neural tube closure and cell proliferation, but is barely detectable in normal differentiated cells . In contrast, YB-1 is highly expressed in cancer cells, and an increasing number of scientific articles have left little doubt that YB-1 promotes tumor growth and drug resistance [15, 16]. Hence, YB-1 has been shown to be a relevant biomarker for clinical outcome of cancer patients [17–19]. Recently, Dunn and colleagues found a link between YB-1 and breast tumor initiating cells. They reported that YB-1 induces breast cancer tumor initiating cells to express CD44 and CD49f leading to enhanced cell growth and drug resistance . Thus, we hypothesized that YB-1 is highly expressed in CSC derived from GBM, too. This assumption is also supported by the finding that the transcription factor Twist, directly involved in generating a breast cancer stem cell phenotype, is highly expressed in GBM , and promotes tumor cell growth through YB-1 expression . Moreover, several essential signaling pathways which are activated in CSC, including signal transducer and activator of transcription (STAT)3, nuclear factor kappa B (NFκB), PKB/AKT and MAPK/ERK are known to target YB-1 [13, 23].
Viruses that replicate selectively in tumor cells but not in normal cells are used as agents to fight cancer. This therapeutic approach is known as virotherapy . Various oncolytic viruses have displayed potential to efficiently kill not only cancer cells, but also CSC [25, 26]. We have previously described the oncolytic adenovirus (OAV) Ad-Delo3-RGD which was rendered cancer-specific by deletion of the transactivation domain CR3 of the E1A13S protein. This deletion restricts viral amplification and anti-tumor activity to drug-resistant cells displaying nuclear YB-1 expression . In addition, Ad-Delo3-RGD contains an E1B19-deletion and a RGD-modified fiber. In a recent study, we have demonstrated the anti-GBM efficacy of Ad-Delo3-RGD in combination with TMZ both in vitro and in vivo.
Based on this knowledge and combined with the observation that high YB-1 expression and/or its nuclear localization are closely associated with poor prognosis in GBM and other malignancies [29, 30], we hypothesize that nuclear YB-1 protein expression due to activated PI3-K/AKT and the RAS/MAPK pathways is significantly elevated in brain CSC, and thus may be useful in ablating CSC by Ad-Delo3-RGD. In the present study we have now analyzed YB-1 protein expression in brain CSC and non-neoplastic tissue. In addition, we examined the capacity of an YB-1 based virotherapy approach in eradicating brain CSC in vitro and in vivo in a TMZ-resistant GBM-CSC model.
U87-MG (ATCC), U373-MG and LN-18 cells (kindly provided by Dr. N. de Tribolet, Zurich, Switzerland) were maintained in DMEM with glutamine (Biochrom, Berlin, Germany) containing 10% FCS (PAN-Biotech, Aidenbach, Germany). Brain CSC lines R11, R28, R40, and R49 were obtained from patients with primary GBM as previously described  and were maintained as tumorspheres in stem cell-permissive DMEM-F12 medium supplemented with 20 ng/ml of each human recombinant epidermal growth factor (EGF; BD Biosciences, Heidelberg, Germany), human recombinant basic fibroblast growth factor (bFGF; R&D Systems, Wiesbaden, Germany), human leukemia inhibitory factor (LIF; Millipore, Billerica, MA, USA), and 2% B27 (Life Technologies, Carlsbad, CA, USA) for preservation of the tumors’ original molecular characteristics and for minor differentiation. SV-GA cells (a human astrocytic subclone of human fetal glial cells transduced with an origin-defective mutant of simian virus 40) have been previously described  and were maintained in MEM medium with 2 mM L-glutamine, 10% fetal bovine serum, and antibiotic solution.
The following viruses were used: (i) wild type adenovirus of serotype 5 (Ad-WT), (ii) Ad-Delo3-RGD, an oncolytic adenovirus (OAV) that combines the dl520 genotype (CR3 deletion of E1A restricting viral amplification and anti-tumor activity to drug-resistant cells displaying nuclear YB-1 expression) with an E1B19K deletion and a RGD motif in the fiber knob , (iii) dl703  that contains expanded deletions in early region 1 (3180 bp) and (iv) the E1A-deleted adenovirus dl312 described in detail in . All viruses were produced in HEK293 cells and purified by two consecutive standard cesium chloride gradient centrifugations and size-exclusion chromatography (PD-10 Desalting Columns, GE Healthcare, Freiburg, Germany). Viral titers were determined by plaque assay using HEK293 cells. Multiplicity of infection (MOI) is therefore indicated as plaque forming units (pfu) per cell. Virus dose was optimized for each in vitro experiment. The absence of replication competent adenovirus (RCA) in Ad-Delo3-RGD preparations was excluded by PCR using specific primers for the E1A-CR3 region (for primer sequences proceed to “DNA isolation and PCR”). In general, particle (determined by OD-measurement) to PFU ratio in virus preparation were between 30 and 50.
Treatment with temozolomide
To calculate the EC50 of TMZ (Schering-Plough, Kenilworth, NJ, USA) in brain CSC lines, the cells were separated by trituation and viability was assessed by trypan blue staining. 10.000 viable brain CSC were treated with increasing concentrations of TMZ (1–2000 μM) for 24 h followed by a medium change. After further 72 h, cell viability was assessed using the MTT assay.
Cells were lysed using ProteoJET Mammalian Cell Lysis Reagent (Fermentas, St. Lon-Rot, Germany) supplemented with complete protease inhibitor cocktail (Roche Diagnostics, Filderstadt, Germany) and incubated at room temperature for 10 min. The lysates were clarified by centrifugation and protein concentration was measured using the Bradford assay. 40 μg protein was separated on SDS-polyacrylamide gels and transferred onto poly-vinylidine-diluloride (PVDF) membranes (Millipore, Schwalbach, Germany). For detection, the following antibodies were used: rabbit anti-phospho-YB1 (Ser102), rabbit PathScan® Multiplex Western Cocktail I (anti-phospho-p90RSK, anti-phospho-AKT, anti-phospho-p44/42 MAPK (Erk1/2), anti-phospho-S6 Ribosomal Protein Detection Kit), rabbit anti-phospho-AKT (all antibodies were purchase from Cell Signaling/Millipore), goat anti-MGMT (R&D Systems) or rabbit anti-YB-1 . Immunoreactive proteins were detected using the Amersham enhanced chemiluminescence (ECL) or ECL plus western blot detection system (GE Healthcare).
DNA isolation and polymerase chain reaction
For the assessment of viral replication, total DNA from infected cells (50 MOI) was isolated using digestion buffer (100 mM NaCl, 10 mM TrisHCl pH 8.0, 25 mM EDTA pH 8.0, 0.5% SDS), Proteinase K and phenol-chloroform. After precipitation with ethanol, DNA was solubilized in 10 mM TrisHCl pH 8.0. Quantitative real-time PCR was performed using the ABI Prism 7900HT sequence detection system (Applied Biosystems) using 100 ng of total DNA per reaction and SYBR green fluorescent dye (Agilent Technologies, Waldbronn, Germany). The specific primers (Eurofins, Hamburg, Germany) used for real-time PCR analyses were: fiber-fw: 5′-AAGCTAGCCCTGCAAACATCA, fiber-rev: 5′-CCCAAGCTACCAGTGGCAGTA, ß-actin-fw: 5′-TAAGTAGGTGCACAGTAGGTCTGA, and ß-actin-rev: 5′-AAAGTGCAAAGAACACGGCTAAG. For identity testing following primer were used: 12Sfw: 5’-AATGGCCGCCAGTCTTTT, 12Srev: 5’-GCCATGCAAGTTAAACATTATC, 13Sfw: 5’-GGCATGTTTGTCTACAGTAAG, 13Srev: 5’-GCCATGCAAGTTAAACATTATC, E1b19kfw: 5’-CGTGAGAGTTGGTGGGCGT, E1b19krev: 5’-CTTCGCTCCATTTATCCT, E3ADPfw: 5’-ATGTCAGCATCTGACTTTGGCC, E3ADPrev: 5’-CTCGAGGAATCATGTCTC, E3fw: 5’-GTTAATGTCAGGTCGCCTAAGTCG, E3rev: 5’-GTGTGTTGCCCGCGACCATT RGDfw: 5’-CTGCCGCGGAGACTGTTTC, RGDrev: 5’-CTGCAATTGAAAAATAAACACG. Cycling conditions started with initial enzyme activation at 95°C for 15 min, followed by 40 cycles of 15 sec denaturation at 95°C, 15 sec, annealing at 60°C, and 15 sec elongation at 72°C. Homogeneity of the amplification product was confirmed by melting curve analysis (Tm-fiber: 85°C, Tm-ß-actin: 83°C). Detection of amplification of the adenoviral sequences E1A12S, E1A13S, E1B19, E3, ADP and RGD (35 cycles, annealing at 55°C) was done by agarose gel electrophoresis.
Immunocytochemistry and immunohistochemistry
Brain CSC were grown on slides and fixed for 20 min in a methanol/acetone (1:1) mixture at −20°C. Immunocytochemical reactions were performed using rabbit anti-YB-1 antibody followed by a FITC-conjugated swine anti-rabbit secondary antibody (1:20; Dako, Hamburg, Germany). Slides were mounted with Vectashield (Vector Laboratories/Axxora, Lörrach, Germany) and images were taken with the AxioImagerZ1 with ApoTome (Zeiss Opticals, Jena, Germany). Immunohistochemical reactions were conducted using polyclonal rabbit antibodies directed against YB-1 as previously described .
Hypoxia and clonogenic dilution assay
R11, R28 or R40 cells were seeded in 12-well plates (1 × 105 cells in 0.5 ml stem cell medium per well) and infected with the indicated viruses the next day. Cells were cultivated for further 24–36 h under normoxic or hypoxic (<0.66% O2) conditions . After this treatment, cells from 12-well plates were diluted for the clonogenic dilution assay into 24-well plates containing 1ml of stem cell medium in 1:10 dilution steps and incubated for approximately 10 doubling times (4–6 weeks).
Inhibition of YB-1 by siRNA
1.5 x 106 R28 cells were transfected with 1000 pmol annealed double-strand control-siRNA (Qiagen, Hilden, Germany; sense 5’-UUCUCCGAACGUGUCACG UdTdT-3’, antisense 5’-ACGUGACACGUUCGGAGAAdTdT-3’)’ or a siRNA specific for YB-1 (Qiagen; sense 5’-GGCGAAGGUUCCCACCUUATT-3’, antisense 5’-UAAGGUGGGAACCUUCGCCTG-3), using Lipofectamine™ 2000 (Life Technologies). After 24 h, cells were divided into three aliquots and infected with 50 MOI dl703, Ad-Delo3-RGD or Ad-WT, respectively. Cells were harvested after 4 h and after 48 h. DNA was isolated as described above and solubilized in 10 mM TrisHCl pH 8.0. Expression of YB-1 was confirmed in cells harvested 48 h after siRNA transfection using immunoblot.
Intracranial tumor model
NMRI nude mice (Janvier, Le Genest Saint Isle, France) were anesthetized and placed into a stereotactic fixation device (Stoelting, Wood Dale, USA). 105 viable R28 cells were injected into the right striatum. At day 7 post implantation, the mice were randomly separated in 4 groups (n=7 to 8 mice per group), followed by an intratumoral injection of either PBS (mock) or 3 x 108 plaques forming units( pfu) Ad-Delo3-RGD. Half of the mice were treated intraperitoneally with TMZ (5 mg/kg) at day 10 and 17. The mice were sacrificed when developing neurological symptoms. Brains were isolated and fixed with 4% paraformaldehyde for further analysis. All animal research was carried out in accordance with the German Animal Welfare Act and was approved by local authorities.
If not other mentioned, figures show representative data from at least three independent experiments. Quantitative data were assessed using t-test. To estimate the potency of Ad-Delo3-RGD in the animal GBM-CSC model, Kaplan-Meier curves were prepared and log-rank analysis was performed using SPSS16.0 (IBM, Stuttgart, Germany). All p-values given are unadjusted, two-sided and subjected to a significance level of 5% (* p=0.05; ** p=0.01; *** p=0.0001).
Tumors of mice were dissected, fixed in 4% formaldehyde, and embedded into paraffin. Serial 5 μm sections were cut and stained with hematoxylin and eosin (H&E). Histopathological evaluations were done on a light microscope (Eclipse E200, Nikon Instruments, Düsseldorf, Germany).
Brain CSC lines express activated AKT and MAPK/ERK
MGMT is differentially expressed in brain CSC lines
TMZ resistance was reported in brain CSC , and different responsiveness to treatment with TMZ according to the MGMT status of these cells was described . Since our set of brain CSCs showed different grades of TMZ resistance (high in R28, low in R11, intermediate in R40 and R49; being EC50 in all CSC higher than the clinical therapeutic TMZ concentration of ~50 μM; data not shown), we tested MGMT expression in these cells using immunoblot analysis. We also included the GBM cell line LN-18 known to express MGMT and being highly resistant to TMZ  as well as U87-MG and U373-MG cells in this analysis. As shown in Figure 1B, MGMT was detectable in LN-18, R28, R40 and R49 cell lines, but not in U87-MG, U373-MG or R11 cells.
Brain CSC lines show high expression of YB-1
YB-1 promotes high level replication of Ad-Delo3-RGD in brain CSC lines
Assessment of adenoviral oncolysis in brain CSC in vitro
Inhibition of YB-1 by siRNA reduces viral replication
Replication profile of Ad-Delo3-RGD in human astrocytes
Based on the observation that nuclear YB-1 expression is a prerequisite of Ad-Delo3-RGD replication we suggested that Ad-Delo3-RGD will be unable to replicate in human non-dividing non-neoplastic brain cells. To confirm this hypothesis, we infected human immortalized SV-GA astrocytic cells with 10 MOI of Ad-Delo3-RGD or Ad-WT and compared particle formation in these cells in comparison to U87MG glioma cells. Ad-WT replication was even better in SV-GA cells compared to U87MG glioma cells (33-fold increase), but replication of the oncolytic adenovirus Ad-Delo3-RGD was markedly and significantly reduced in SV-GA cells compared to U87MG cells (Figure 5D).
High therapeutic impact and good safety profile of Ad-Delo3-RGD in a mouse orthotopic TMZ resistant GBM/CSC brain tumor model
It is well established that GBM show increased activation of different signaling pathways including PI3-K/AKT and MAPK/ERK. Signaling through both ERK and AKT is implicated in drug resistance and cell invasion [44, 45]. The same has been described for CSC of the brain. Drug resistance and invasive growth are features that make this tumor so difficult to treat. Beside this, identification of CSC in GBM has been found to be of prognostic value [46, 47].
Several lines of evidence have indicated a close relationship of YB-1 function and PI3-K/AKT and MAPK/ERK mediated signaling in tumor cells, including direct phosphorylation of YB-1 (serine102) by AKT and by RSK, a downstream player of the MAPK signaling cascade, thereby affecting cellular localization and biological function of YB-1 [13, 48]. YB-1 in its function as a transcription factor regulates gene expression by binding to promoter regions containing a Y-box motif. Amongst others, YB-1 activates gene expression of the epidermal growth factor receptor (EGFR), matrix metalloproteinase 2 (MMP-2) and of the receptor tyrosine kinase c-MET, all this associated with tumor cell adhesion, invasion and metastasis. Thus, YB-1 could be positioned as a key player in the PI3-K/AKT and MAPK pathways . Mentionable is also the observation, that YB-1 expression is regulated by Twist, which in turn is transcriptionally induced by STAT3. Both are known to play an important role in epithelial to mesenchymal transition (EMT), maintenance of cancer initiating cells and multidrug resistance [50, 51].
The importance of YB-1 in conferring multidrug resistance is well documented [13, 16]. The role of YB-1 in cancer initiation has, until recently, not been investigated. Dunn and colleagues have shown that blocking YB-1 protein expression delayed tumor onset in mice. In addition, they demonstrated that YB-1 is involved in tumor initiating surface marker expression, including CD44 in breast cancer initiating cells. Based on these findings, they postulate that MAPK/RSK phosphorylation and activation of its downstream targets, including YB-1, promote a cancer initiating phenotype .
In a first step, we examined the above mentioned pathways, which turned out to be generally activated in brain CSC (Figure 1A). Next, we studied the downstream target YB-1. We found considerable expression as well as phosphorylation and therefore activation of YB-1 in all brain CSC and GBM cell lines analyzed so far, but not in non-neoplastic brain tissue (Figure 2). This is in line with previous studies that evaluated YB-1 expression in pediatric primary GBM and non-neoplastic brain tissue . However, even if the major fraction of GBM expresses YB-1, its expression level and subcellular localization varies among tumors of different patients (Figure 2C). Since it is known that YB-1 will be up-regulated as well as activated by phosphorylation and nuclear localization in patients who initially have been treated with radio-chemotherapy, the detected variability of YB-1 expression in different GBM specimen may be a result of different chemotherapy approaches and different cycles of chemotherapy the patients received. This fact makes Ad-Delo3-RGD treatment of patients with recurrent GBM, who achieved chemo-radiotherapy, an interesting virotherapeutic strategy, since notably these patients will present high amounts of activated YB-1 in their tumor cells.
On the one hand, YB-1 like Twist is capable to induce EMT in some tumor entities  but on the other hand, EMT has been reported to be linked to the gain of epithelial stem cell properties . In addition, migrating GBM cells showing a stemness-like phenotype are characterized by expressing high levels of CD44 and low levels of programmed cell death protein (PDCD)4, a factor known to inhibit YB-1 expression . Taken together, our data support the idea of Dunn and colleagues that YB-1 might promote a cancer initiating phenotype. However, the role of YB-1 in brain CSC tumorigenicity remains to be studied in detail and was beyond the scope of this work.
It has been reported that embryonal carcinoma stem cells support adenoviral replication more efficiently than differentiated derivatives, hypothesizing that a cellular factor with E1A-like activity is regulated during differentiation in stem cells . We have previously reported that the recombinant adenovirus Ad-Delo3-RGD, containing a certain deletion in the E1A gene, replicates in nuclear YB-1 positive cancer cells . We used Ad-Delo3-RGD which contained a RGD motif to increase infectivity in glioma cells. However, brain CSC show high CAR expression; hence the infection of CSC occurs also independent from RGD-fiber modification (data not shown). Here we demonstrate efficient viral replication in and cell killing of brain CSC lines by Ad-Delo3-RGD under normoxic and even under hypoxic conditions (Figure 3, 4). OAV like Ad-Delo3-RGD have displayed the potential to efficiently kill not only differentiated cancer cells, but also CSC, including CD44high/CD24low cancer breast cells and CD133high glioma CSC [25, 26]. However, this is the first report showing that YB-1, which is highly expressed in CSC lines, facilitates adenovirus replication. This is in line with recently published data illustrating that YB-1 is commonly expressed in primary brain CSC and that its expression increased with tumor grade .
We next examined the therapeutic anti-tumor efficacy of Ad-Delo3-RGD in an intracranial, orthotopic mouse model using MGMT expressing, TMZ-resistant R28 CSC (Figure 1B). This GBM animal model reflects clinical reality better than using established GBM cell lines. Radiotherapy in combination with the alkylating agent TMZ is currently the standard of care for GBM. GBM expressing MGMT due to an unmethylated MGMT promoter show resistance to treatment with TMZ [57, 58]. Furthermore, patients presenting an unmethylated MGMT promoter do not or only marginally benefit from TMZ treatment . Whereas the treatment of R28-GBM bearing mice with TMZ had, as expected no effect, intratumoral injection of Ad-Delo3-RGD significantly prolonged survival of mice. No further increase in survival was observed when Ad-Delo3-RGD injection was combined with TMZ treatment (Figure 6A). This was not unexpected since initial in vitro experiments using R28 cells did not indicate any additive or even synergistic inhibition of brain CSC growth when adenoviral infection was combined with TMZ treatment (data not shown). However, the results are in contrast to published data using TMZ resistant melanoma cell of unknown MGMT status  or established GBM cell lines . In this context it is mentionable that ionizing radiation (IR) strongly induces YB-1 phosphorylation, enhances repair of DNA double-stranded breaks and affects cell survival . Since current standard of care for patients with GBM includes IR, which is a strong activator of the PI3-K/AKT and MAPK/ERK pathways and promote radio-resistance by activation of the DNA damage response [62, 63], it would be interesting or even necessary to include IR in future combinatorial treatment studies.
During treatment of R28-GBM bearing mice, we intratumorally applied 3 x 108 pfu Ad-Delo3-RGD. This is, compared to human, a lower virus load than the well-tolerated dose of the OAV ONYX-015 evaluated for human . Using this dose, microscopic examinations of brain tissues of Ad-Delo3-RGD treated mice showed no signs of inflammation or other related toxicity in adjacent, tumor-surrounding healthy brain, including the subventricular zone, cerebellum and cerebrum, indicating the safety of this YB-1 based virotherapy approach. In addition, our experiments showed, that (i) replication of Ad-Delo3-RGD depends on the presence of YB-1 in cancer stem-like cells, and (ii) Ad-Delo3-RGD only marginally replicates in human immortalized astrocytes (Figure 5). The fact that YB-1 is highly expressed in cancer cells compared to non-neoplastic brain tissue suggests that an YB-1 based virotherapy approach has a high therapeutic index. However, extensive toxicity and biodistribution studies are still necessary to confirm the safety of Ad-Delo3-RGD.
The results reported here demonstrate that YB-1 is highly expressed in brain cancer stem cell lines and unambiguously, that these cells were efficiently killed by YB-1 dependent OAV in vitro, leaving non-neoplastic astrocytes unattached. Mean survival of Ad-Delo3-RGD treated R28-bearing mice was significantly longer than that of control mice. To develop new virotherapeutic strategies for GBM, our data are of clinical relevance since it is believed that brain CSC are critical for GBM maintenance and recurrence. In addition, YB-1 expression is linked to multidrug- and radio-resistance and has been repeatedly described to be a predictive biomarker. Even knowing that YB-1 will be upregulated by chemo- as well as radiotherapy, YB-1 analysis of GBM biopsies might improve the therapeutic decision making process in a clinical setting and can help to identify patients who will benefit from novel YB-1 based virotherapy.
The authors would like to thank D. Hellmann, H. Kalvelage and S. Michailidou for excellent technical assistance. This work was supported in part by grants obtained from the BMBF project “Innovative Therapies” (01GU0613) and grants from the Klinikum rechts der Isar, Technische Universität München, Munich, Germany, to PSH. Parts of the project were funded by the career award to young female scientists of the RWTH Aachen, Medical School.
- Lacroix M, Abi-Said D, Fourney DR: A multivariate analysis of 416 patients with glioblastoma multiform: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95: 190-198. 10.3171/jns.2001.95.2.0190.View ArticlePubMedGoogle Scholar
- Stupp R, Mason WP, van den Bent MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.View ArticlePubMedGoogle Scholar
- Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 415: 105-111.View ArticleGoogle Scholar
- Ailles LE, Weisman IL: Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007, 18: 460-466. 10.1016/j.copbio.2007.10.007.View ArticlePubMedGoogle Scholar
- Das S, Srikanth M, Kessler JA: Cancer stem cells and glioma. Nat Clin Pract. 2008, 4: 427-435.View ArticleGoogle Scholar
- Singh SK, Clarke ID, Terasaki M: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63: 5821-5828.PubMedGoogle Scholar
- Bao S, Wu Q, Mclendon RE: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444: 756-760. 10.1038/nature05236.View ArticlePubMedGoogle Scholar
- Blough MD, Westgate MR, Beauchamp D: Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol. 2010, 12: 756-760. 10.1093/neuonc/noq032.PubMed CentralView ArticlePubMedGoogle Scholar
- Beier D, Röhrl S, Pillai DR: Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008, 68: 5706-5715. 10.1158/0008-5472.CAN-07-6878.View ArticlePubMedGoogle Scholar
- Bleau A, Hambardzumyan D, Ozawa T: PTEN/PI3K/AKT pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009, 4: 226-235. 10.1016/j.stem.2009.01.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Molina JR, Hayashi Y, Stephens C, Georgescu MM: Invasive glioblastoma cells acquire stemness and increased AKT activation. Neoplasia. 2010, 12: 453-463.PubMed CentralView ArticlePubMedGoogle Scholar
- Sunayama J, Matsuda KI, Sato A: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 2010, 28: 1930-1939. 10.1002/stem.521.View ArticlePubMedGoogle Scholar
- Wu J, Stratford AL, Astanehe A: YB-1 is a transcription/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics. 2007, 2: 49-65.PubMed CentralPubMedGoogle Scholar
- Lu ZH, Books JT, Ley TJ: YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol. 2005, 25: 4625-4637. 10.1128/MCB.25.11.4625-4637.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Schittek B, Psenner K, Sauer B: The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer. 2007, 120: 2110-2118. 10.1002/ijc.22512.View ArticlePubMedGoogle Scholar
- Bargou RC, Jürchott K, Wagener C: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Med. 1997, 3: 378-380. 10.1038/nm0497-378.View ArticleGoogle Scholar
- Kashihara M, Azuma K, Kawahara A: Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 2009, 4: 1066-1074. 10.1097/JTO.0b013e3181ae2828.View ArticlePubMedGoogle Scholar
- Oda Y, Ohishi Y, Basaki Y: Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer:their correlation with activated Akt. LRP/MVP and P-glycoprotein expression. Cancer Sci. 2007, 98: 1020-1026. 10.1111/j.1349-7006.2007.00492.x.View ArticlePubMedGoogle Scholar
- Gessner C, Woischwill C, Schumacher A: Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir. 2004, 23: 14-19. 10.1183/09031936.03.00033203.View ArticleGoogle Scholar
- To K, Fotovati A, Reispas KM: Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70: 2840-2851. 10.1158/0008-5472.CAN-09-3155.PubMed CentralView ArticlePubMedGoogle Scholar
- Elias MC, Tozer KR, Silber JR: Twist is expressed in human gliomas and promotes invasion. Neoplasia. 2005, 9: 824-837.View ArticleGoogle Scholar
- Shiota M, Izumi H, Onitsuka T: Twist Promotes tumor cell growth through YB-1 expression. Cancer Res. 2008, 68: 98-105. 10.1158/0008-5472.CAN-07-2981.View ArticlePubMedGoogle Scholar
- Jürchott K, Kuban RJ, Krech T: Identification of y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signature in colorectal cancer cells. Plos Genetics. 2010, 6: 1-19.View ArticleGoogle Scholar
- Chu RL, Post DE, Khuri FR, Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004, 10: 5299-5312. 10.1158/1078-0432.CCR-0349-03.View ArticlePubMedGoogle Scholar
- Jiang H, Gomez-Manzano C, Aoki H: Examination of the therapeutic potential of delta-24-rgd in brain tumor stem cells: Role of autophagic cell death. J Nat Cancer. 2007, 99: 1410-1414. 10.1093/jnci/djm102.View ArticleGoogle Scholar
- Eriksson M, Guse K, Bauerschmitz G, Virkkunen P: Oncolytic adenoviruses kill breast initiating CD44 + CD24-/low cells. Mol Ther. 2007, 15: 2088-2093. 10.1038/sj.mt.6300300.View ArticlePubMedGoogle Scholar
- Rognoni E, Widmaier M, Haczek C: Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. Cancer Gene Ther. 2009, 16: 753-763. 10.1038/cgt.2009.20.View ArticlePubMedGoogle Scholar
- Holzmüller R, Mantwill K, Haczek C: YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer. 2011, 129: 1265-1276. 10.1002/ijc.25783.View ArticlePubMedGoogle Scholar
- Faury D, Nantel A, Dunn SE: Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007, 25: 1196-1208. 10.1200/JCO.2006.07.8626.View ArticlePubMedGoogle Scholar
- Janz M, Harbeck N, Dettmar P: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002, 97: 278-82. 10.1002/ijc.1610.View ArticlePubMedGoogle Scholar
- Beier D, Hau P, Proescholdt M, Lohmeier A: CD133+ and CD133− glioblastoma derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67: 4010-4015. 10.1158/0008-5472.CAN-06-4180.View ArticlePubMedGoogle Scholar
- Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J: Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A. 1985, 82: 1257-1261. 10.1073/pnas.82.4.1257.PubMed CentralView ArticlePubMedGoogle Scholar
- Bett AJ, Haddara W, Prevec L, Graham FL: An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A. 1994, 91: 8802-8806. 10.1073/pnas.91.19.8802.PubMed CentralView ArticlePubMedGoogle Scholar
- Nevins JR: Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell. 1981, 1981 (26): 213-220.View ArticleGoogle Scholar
- Glockzin G, Mantwill K, Jurchott K: Characterization of the Recombinant Adenovirus Vector AdYB-1: Implications for Oncolytic Vector Development. J. Virology. 2006, 80: 3904-3911. 10.1128/JVI.80.8.3904-3911.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Schilling D, Gehrmann M, Steinem C: Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 2009, 23: 2467-2477. 10.1096/fj.08-125229.PubMed CentralView ArticlePubMedGoogle Scholar
- Coles LS, Lambrusco L, Burrows J: Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett. 2005, 579: 5372-5378. 10.1016/j.febslet.2005.08.075.View ArticlePubMedGoogle Scholar
- Sutherland BW, Kucab J, Wu J: Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005, 24: 4281-4292. 10.1038/sj.onc.1208590.View ArticlePubMedGoogle Scholar
- Stratford AL, Fry CJ, Desilets C: Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008, 10: R99-10.1186/bcr2202.PubMed CentralView ArticlePubMedGoogle Scholar
- Hermisson M, Klumpp A, Wick W: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006, 96: 766-776. 10.1111/j.1471-4159.2005.03583.x.View ArticlePubMedGoogle Scholar
- Holm PS, Bergmann S, Jürchott K: YB-1 relocates to the nucleus in adenovirus infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Bio Chem. 2002, 277: 10427-10434. 10.1074/jbc.M106955200.View ArticleGoogle Scholar
- Mantwill K, Koehler-Vargas N, Bernshausen A: Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res. 2006, 66: 7195-7202. 10.1158/0008-5472.CAN-05-2339.View ArticlePubMedGoogle Scholar
- Schäfer A, Teufel J, Ringel F: Aldehyde dehydrogenase 1A1 – a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol. 2012, 12: 1452-1464.View ArticleGoogle Scholar
- Abrams SL, Steelman LS, Shelton JG: The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle. 2010, 9: 1781-1791. 10.4161/cc.9.9.11483.PubMed CentralView ArticlePubMedGoogle Scholar
- McCubrey JA, Steelman LS, Abrams SL: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006, 46: 249-279. 10.1016/j.advenzreg.2006.01.004.View ArticlePubMedGoogle Scholar
- Murat A, Migliavacca E, Gorlia T: Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008, 26: 3015-3024. 10.1200/JCO.2007.15.7164.View ArticlePubMedGoogle Scholar
- Pallini R, Ricci-Vitiani L, Banna GL: Cancer stem cell analysis and clinical out come in patients with glioblastoma multiforme. Clin Cancer Res. 2008, 14: 8205-8212. 10.1158/1078-0432.CCR-08-0644.View ArticlePubMedGoogle Scholar
- Shen H, Xu W, Luo W: Upregulation of mdr1 gene is related to activation of the MAPK/ERK signalling transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol. 2011, 39: 558-569. 10.1016/j.exphem.2011.01.013.View ArticlePubMedGoogle Scholar
- Davies AH, Dunn SE: YB-1 drives preneoplastic progression: insight into opportunities for cancer prevention. Oncotarget. 2011, 2: 401-406.PubMed CentralView ArticlePubMedGoogle Scholar
- Villalva C, Martin-Lanneree S, Cortes U: STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastoma: a potential for targeted therapy?. Int J Cancer. 2011, 128: 826-838. 10.1002/ijc.25416.View ArticlePubMedGoogle Scholar
- Sherry MM, Reeves A, WU JK, Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009, 27: 2383-2392. 10.1002/stem.185.PubMed CentralView ArticlePubMedGoogle Scholar
- Evdokimova V, Tognon C, Ng T: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009, 15: 357-359. 10.1016/j.ccr.2009.04.006.View ArticleGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.PubMed CentralView ArticlePubMedGoogle Scholar
- Shiota M, Izumi H, Tanimoto A: Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res. 2009, 69: 3148-3156.View ArticlePubMedGoogle Scholar
- Thangue N, Rigby P: An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell. 1987, 49: 507-513. 10.1016/0092-8674(87)90453-3.View ArticlePubMedGoogle Scholar
- Fotovati A, Abu-Ali S, Wang PS: YB-1 bridges neural stem cells and brain tumor initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011, 71: 5569-5578. 10.1158/0008-5472.CAN-10-2805.View ArticlePubMedGoogle Scholar
- Hegi ME, Diserens AC, Gorlia T: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352: 997-1003. 10.1056/NEJMoa043331.View ArticlePubMedGoogle Scholar
- Esteller M, Garcia-Foncillas J, Andion E: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. Engl J Med. 2000, 343: 1350-1354. 10.1056/NEJM200011093431901.View ArticleGoogle Scholar
- Stupp R, Hegi ME, Mason WP, van den Bent MJ: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7.View ArticlePubMedGoogle Scholar
- Quirin C, Mainka A, Hesse A, Nettelbeck DM: Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int J Cancer. 2007, 121: 2801-2807. 10.1002/ijc.23052.View ArticlePubMedGoogle Scholar
- Toulany M, Schlickfluß TA, Eicheler W: Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 2011, 13: R28-10.1186/bcr2845.PubMed CentralView ArticlePubMedGoogle Scholar
- Shideng B, Qiulian W, McLendon RE: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444: 756-759. 10.1038/nature05236.View ArticleGoogle Scholar
- Wl T, Yip GW, Tan PH: Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoresistance in nasopharyngeal cancer. Mod. Pathology. 2009, 22: 282-290. 10.1038/modpathol.2008.181.View ArticleGoogle Scholar
- Kirn D: Oncolytic virotherapy for cancer with the adenovirus dl520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Therapy. 2001, 3: 525-538.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.